Brenda Eap, PhD

As promised, our agenda is finally announced!!

Thank you for highlighting the momentum we have been building since our inaugural event in 2024, @LongevityTech! Incredible to see how far the conversation has moved from speculative science to serious national policy in just three years. Read it here: longevity.technology/news/h-span-re… @bioagelabs @RetroBio_ @KarlPfleger @soniaarrison @mkaeberlein @DrMikeRoizen @BuckInstitute @aubreydegrey

This is the most ambitious agenda we’ve put together so far!

I’m thrilled to announce my new podcast, Longevity Science with Matt Kaeberlein. Episode 1 is now live and takes a deep dive into the story of dinitrophenol (DNP) — an experimental weight loss drug linked to hundreds of deaths and a cautionary reminder of what can happen when enthusiasm for new therapies gets ahead of the science. Episode 2 drops Friday and features a Longevity Roundtable with @BKennedy_aging and @docmranney . We discuss proactive healthcare, rapamycin, peptides, epigenetic reprogramming, biological age testing, and where the field of longevity medicine may be headed next. My goal with this channel is simple: thoughtful, evidence-based conversations that separate signal from noise in the rapidly evolving world of longevity science. I hope you’ll check it out — and subscribe on YouTube, Spotify, or wherever you listen to podcasts. YouTube: @mkaeberlein" target="_blank" rel="nofollow noopener">youtube.com/@mkaeberlein Spotify: open.spotify.com/show/7DRRH5lfL…

The passage of HB 1734 and HB 1735 is a no-brainer, and it is disappointing how much pushback it is receiving from the “pro-business,” “pro-freedom” and “pro-life” Republicans on the Senate Health and Human Services Committee. There are countless lives that can be helped — from early stage chronic disease to rare disease patients, all of whom have no other options. If you live in NH, call your Senators and demand these bills get passed. If you know someone in NH, do the same. @KellyAyotte — thank you for your support, your leadership, and your ability to see things clearly and with reason. @roche4nh — you are making lives worse and actively hurting your state. As a pharmacist, you of all people should understand what’s at stake for patients who have run out of options. You still have a chance to get this right. Do the right thing.

The Alliance for Longevity Initiatives (A4LI) would like to provide an update regarding New Hampshire’s ongoing efforts to expand patient access to investigational medical treatments and strengthen the state’s position as a hub for biomedical innovation. This week, legislative language from HB1734 and HB1735 was successfully attached to SB504 through the amendment process in the New Hampshire House of Representatives, keeping these reforms active as negotiations continue. HB1734 would authorize the establishment of experimental treatment centers capable of offering eligible investigational therapies under state oversight, while HB1735 would expand New Hampshire’s Right to Try framework to include patients suffering from chronic and debilitating conditions We would especially like to thank House Speaker Sherman Packard (@NHSpeaker) and Majority Leader Jason Osborne (@Osborne4NH) for their leadership and continued support. Together, these proposals continue New Hampshire’s emergence as one of the most forward-looking states in the country on medical innovation, patient autonomy, and access to next-generation therapies. As the process continues, we encourage everyone to respectfully reach out to Senate President Sharon Carson, Senator Rochefort, and Senator Birdsell and urge them to support SB504 as amended during committee of conference negotiations. We look forward to continuing to work with lawmakers, patients, advocates, and innovators as this effort progresses.

@KrisMBarnes I agree!!

I love the framing of this graphic. It may be the first time I’ve seen the aging hallmarks and tissue level aging diseases in one graphic. It feels tractable and makes you appreciate how much medicine is advancing in many of these areas.

𝐖𝐞 𝐚𝐫𝐞 𝐥𝐢𝐯𝐢𝐧𝐠 𝐥𝐨𝐧𝐠𝐞𝐫, 𝐛𝐮𝐭 𝐰𝐞 𝐚𝐫𝐞𝐧'𝐭 𝐥𝐢𝐯𝐢𝐧𝐠 𝐡𝐞𝐚𝐥𝐭𝐡𝐢𝐞𝐫. Sixty percent of the global disease burden is now tied to chronic, age-related conditions. We are trading quick deaths for decades of disability, and it’s time for the NIH to fund the solution, not just manage the decline. As the NIH requests input for its Strategic Plan for FY 2027-2031, the Alliance for Longevity Initiatives is proposing a Disease-Burden Framework. Our proposal recommends that research funding be allocated by actual disease burden, measured by DALYs (Disability-Adjusted Life Years) from the Global Burden of Disease Study. This isn't a new concept—a framework like this already exists with the Onco-Aging Consortium within the NCI and NIA. Now, it’s time to expand this successful model across all major disease institutes—NHLBI, NIDDK, NEI, NINDS, and NIDCD. 𝐖𝐡𝐢𝐜𝐡 𝐢𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐞 𝐝𝐨 𝐲𝐨𝐮 𝐭𝐡𝐢𝐧𝐤 𝐰𝐨𝐮𝐥𝐝 𝐛𝐞𝐧𝐞𝐟𝐢𝐭 𝐦𝐨𝐬𝐭 𝐟𝐫𝐨𝐦 𝐚 𝐟𝐨𝐫𝐦𝐚𝐥 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐍𝐈𝐀? 𝐋𝐞𝐭'𝐬 𝐝𝐢𝐬𝐜𝐮𝐬𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐦𝐞𝐧𝐭𝐬. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐩𝐫𝐨𝐩𝐨𝐬𝐚𝐥 𝐚𝐧𝐝 𝐬𝐢𝐠𝐧 𝐨𝐧 𝐲𝐨𝐮𝐫 𝐬𝐮𝐩𝐩𝐨𝐫𝐭: 🔗actionnetwork.org/petitions/real…

@theA4LI Institutes like the NEI and NIDCD play an understated yet critical role in longevity. These institutes protect the sensory inputs that define our quality of life and we often take them for granted, so I'm excited and very supportive of these consortia with the NIA!

@theA4LI @US_FDA Really looking forward to this panel with @bioagelabs and Kitalys!

We are honored to announce Lowell M. Zeta, @US_FDA Deputy Commissioner for Strategic Initiatives and Special Counsel, as a featured speaker at our upcoming H-SPAN Summit D.C. Lowell will be joining a distinguished panel to discuss FDA Strategies for Longevity Medicine. His expertise in navigating complex regulatory landscapes and his leadership in cross-agency innovation will provide invaluable insights into the regulatory frameworks and strategic initiatives necessary to bring transformative aging-related therapies to the public. Get your ticket today! Full agenda here: a4li.org/h-span-summit-…

@theA4LI @US_FDA Really looking forward to this panel with @bioagelabs and Kitalys!

Talks from our H-SPAN Arizona event are now uploaded on our YouTube channel: tinyurl.com/rxzztdm9 @azcommerce @AZTechWeek @ZuberLawler @VensureHR @ASU @UAZBIO5 @UAZPharmacy @BuckInstitute @Hexoskin @GoldwaterInst @OraBiomedical

This paper exists because teams of people started an unglamorous data collection project many years ago. The Interventions Testing Program (ITP) is a long-running project by the NIH-NIA with the goal to identify interventions that extend lifespan in mice. The ITP was not built around the analysis this paper eventually performed. Instead, the paper’s method emerged because a group of scientists had access to a sufficiently large dataset generated by the ITP and realized there were better questions to ask of it. Computational power is scaling rapidly. What isn't scaling is the generation of biological data that requires organisms to age, populations to evolve, or longitudinal measurements to accumulate across years. If someone starts a 10-year dataset now, by the time it matures the analytical tools available to interrogate it will be dramatically more powerful than anything we have today. But if nobody starts the dataset, those tools have nothing to work with. For those thinking about the overall progress of longevity, it’s now obvious that AI will be bottlenecked by the lack of high quality biological datasets. nature.com/articles/s4158…

@KrisMBarnes Woot woot!!

Really excited to be speaking at the H-SPAN summit this year in DC. The A4LI team do an excellent job at spearheading the political efforts required for building a future where robustly efficacious treatments for aging disease are available to patients.

@theA4LI @soniaarrison @KarlPfleger @mkaeberlein @bettslacroix @KeithComito @eric_k_morgen @bioagelabs @DToddWhite @H_L_Clinic @GenerationLab_ I'm really looking forward to the "Translating Geroscience from Lab to Patients" panel! Dr. Stephen Kritchevsky (@agingup), @OcanasSR, @DrMorganLevine, and Dr. Hanadie Yousef will have very different perspectives to share.

Today’s the day! The H-SPAN Summit D.C. agenda is officially LIVE! Check out our incredible lineup of sessions and speakers here: a4li.org/h-span-summit-… Let us know who you’re most excited to see by commenting below! For the next week, get 20% off a ticket using promo code: HEALTHSPAN

What an epic line-up!

It came together so nicely! Beyond grateful to everyone who was so game to come speak!! Thanks @AZTechWeek for the opportunity. Until next year! ✌️

Come hike!!!! Excited to get people together again!

Big news at the Buck: world-renowned cell biologist Peter Walter, PhD, has joined our faculty. His discoveries transformed our understanding of how cells maintain health—and what happens when that breaks down in aging and disease. Welcome, Peter! buckinstitute.org/news/the-buck-…

Finally—this is the kind of study the field has been waiting for. A 720-person randomized clinical trial testing low-dose rapamycin in adults 65+ is about to get underway at @UAZPharmacy , with the goal of answering a simple but critical question: can we actually improve healthspan in humans? In this episode, I sit down with Dr. Bonnie LaFleur to break down the design, the science, and why this trial is different: • Real clinical endpoints (frailty + inflammation) • Long-term follow-up (years, not weeks) • Deep phenotyping—genetics, epigenetics, immune profiles, and more • Early data suggesting no major safety signals at weekly dosing We also dig into what we still don’t know—pharmacokinetics, individual variability, and whether rapamycin can truly shift the trajectory of aging in people. This is a big moment for the field. Not hype. Not speculation. Data. 🎧 Full episode here: youtube.com/watch?v=yAV7BR…